Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -393.68% is 284% below its 5-year average of -102.52%, near the low end of its 5-year range (-393.68%–-49.01%).
102.22% below its 12-month average of -194.68%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -123.09%.
RETURN ON ASSETS (ROA)
-393.68%
RETURN ON ASSETS (ROA) AVG TTM
-194.68%
RETURN ON ASSETS (ROA) AVG 3Y
-123.06%
RETURN ON ASSETS (ROA) AVG 5Y
-102.52%
RETURN ON ASSETS (ROA) AVG 10Y
-109.11%
RETURN ON ASSETS (ROA) AVG 15Y
-83.86%
RETURN ON ASSETS (ROA) AVG 20Y
-77.16%
CURRENT VS TTM AVG
-102.22%
CURRENT VS 3Y AVG
-219.90%
CURRENT VS 5Y AVG
-284.01%
CURRENT VS 10Y AVG
-260.82%
CURRENT VS 15Y AVG
-369.46%
CURRENT VS 20Y AVG
-410.19%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1121.09%
vs the sector median at left
Oncolytics Biotech Inc.
Market Cap
$60.02M
Return on Assets (ROA)
-393.68%
TTM Avg
-194.68%
3Y Avg
-123.06%
5Y Avg
-102.52%
Market Cap
$60.42M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$59.18M
Return on Assets (ROA)
-14.15%
TTM Avg
-52.30%
3Y Avg
-73.34%
5Y Avg
-79.94%
Market Cap
$58.44M
Return on Assets (ROA)
-382.32%
TTM Avg
-98.02%
3Y Avg
-80.35%
5Y Avg
-65.77%
Market Cap
$58.43M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$58.29M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$58.06M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
Market Cap
$57.76M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$57.61M
Return on Assets (ROA)
-56.24%
TTM Avg
-59.70%
3Y Avg
-30.02%
5Y Avg
-37.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $60.02M | -393.68% | -194.68% | -123.06% | -102.52% |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | -128.88% | -89.84% | -89.26% | -80.42% |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | -14.15% | -52.30% | -73.34% | -79.94% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | -382.32% | -98.02% | -80.35% | -65.77% |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | -66.80% | -56.95% | -50.95% | -40.99% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | -118.15% | -138.13% | -224.99% | -221.92% |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | -44.47% | -42.63% | -230.85% | -167.04% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | -37.05% | -34.36% | -41.63% | -37.74% |
| Talphera, Inc. (TLPH)vs › | $57.61M | -56.24% | -59.70% | -30.02% | -37.67% |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | -107.09% | -123.27% | -270.15% | -219.64% |
ROA
-393.7%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -276.44% |
| 2024-12-31 | -112.91% |
| 2023-12-31 | -53.89% |
| 2022-12-31 | -49.01% |
| 2021-12-31 | -57.33% |
| 2020-12-31 | -65.53% |
| 2019-12-31 | -231.73% |
| 2018-12-31 | -114.61% |
| 2017-12-31 | -86.04% |
| 2016-12-31 | -102.59% |
| 2015-12-31 | -50.11% |
| 2014-12-31 | -108.29% |
| 2013-12-31 | -83.38% |
| 2012-12-31 | -164.75% |
| 2011-12-31 | -80.62% |
| 2010-12-31 | -44.95% |
| 2009-12-31 | -45.60% |
| 2008-12-31 | -125.47% |
| 2007-12-31 | -50.82% |
| 2006-12-31 | -42.60% |
| 2005-12-31 | -27.61% |
| 2004-12-31 | -32.81% |
| 2003-12-31 | -32.80% |
| 2002-12-31 | -33.90% |
| 2001-12-31 | -32.36% |
| 2000-12-31 | -16.68% |
| 1999-12-31 | -8.02% |
